Century Therapeutics’ (IPSC) “Buy” Rating Reiterated at Guggenheim

Guggenheim reissued their buy rating on shares of Century Therapeutics (NASDAQ:IPSC) in a research report released on Friday,Benzinga reports.

Several other research firms also recently issued reports on IPSC. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Century Therapeutics in a report on Wednesday, January 22nd. Chardan Capital cut their price target on shares of Century Therapeutics from $11.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, March 24th. Finally, Piper Sandler decreased their price target on shares of Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating for the company in a research report on Thursday, March 20th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $5.00.

Century Therapeutics Price Performance

Shares of IPSC opened at $0.51 on Friday. The firm has a 50-day simple moving average of $0.71 and a two-hundred day simple moving average of $1.12. The stock has a market cap of $44.13 million, a PE ratio of -0.28 and a beta of 1.75. Century Therapeutics has a 1-year low of $0.51 and a 1-year high of $4.43.

Century Therapeutics (NASDAQ:IPSC) last posted its earnings results on Wednesday, March 19th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.02. The firm had revenue of $4.18 million during the quarter, compared to the consensus estimate of $0.67 million. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. As a group, sell-side analysts expect that Century Therapeutics will post -1.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Century Therapeutics

A number of large investors have recently modified their holdings of IPSC. Casdin Capital LLC grew its stake in shares of Century Therapeutics by 61.6% during the fourth quarter. Casdin Capital LLC now owns 5,190,506 shares of the company’s stock worth $5,242,000 after purchasing an additional 1,978,190 shares in the last quarter. Millennium Management LLC boosted its position in shares of Century Therapeutics by 1,041.8% during the 4th quarter. Millennium Management LLC now owns 1,607,174 shares of the company’s stock worth $1,623,000 after acquiring an additional 1,466,415 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Century Therapeutics by 146.4% in the 4th quarter. Renaissance Technologies LLC now owns 1,202,885 shares of the company’s stock valued at $1,215,000 after acquiring an additional 714,685 shares during the last quarter. Deutsche Bank AG increased its holdings in shares of Century Therapeutics by 890.7% in the 4th quarter. Deutsche Bank AG now owns 193,368 shares of the company’s stock valued at $195,000 after acquiring an additional 173,849 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new stake in shares of Century Therapeutics during the 3rd quarter worth about $284,000. 50.20% of the stock is owned by hedge funds and other institutional investors.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.